These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16319226)

  • 1. NICE discrimination.
    Rawlins M; Dillon A
    J Med Ethics; 2005 Dec; 31(12):683-4; discussion 685-8. PubMed ID: 16319226
    [No Abstract]   [Full Text] [Related]  

  • 2. Toward a broader view of values in cost-effectiveness analysis of health.
    Menzel P; Gold MR; Nord E; Pinto-Prades JL; Richardson J; Ubel P
    Hastings Cent Rep; 1999; 29(3):7-15. PubMed ID: 10420299
    [No Abstract]   [Full Text] [Related]  

  • 3. Searching for a threshold - Not so NICE..
    Mooney G; Coast J; Jan S; ; Ryan M; Wiseman V
    J Health Serv Res Policy; 2007 Jul; 12(3):190; author reply 190-1. PubMed ID: 17716427
    [No Abstract]   [Full Text] [Related]  

  • 4. It's not NICE to discriminate.
    Harris J
    J Med Ethics; 2005 Jul; 31(7):373-5. PubMed ID: 15994352
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacogenetic interventions, orphan drugs, and distributive justice: the role of cost-benefit analysis.
    Rai AK
    Soc Philos Policy; 2002; 19(2):246-70. PubMed ID: 12678089
    [No Abstract]   [Full Text] [Related]  

  • 6. Resource allocation for control of infectious diseases in multiple independent populations: beyond cost-effectiveness analysis.
    Brandeau ML; Zaric GS; Richter A
    J Health Econ; 2003 Jul; 22(4):575-98. PubMed ID: 12842316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unintended consequences of applying economic evaluation.
    Oliver A
    J Health Serv Res Policy; 2002 Jul; 7(3):129-30. PubMed ID: 12171741
    [No Abstract]   [Full Text] [Related]  

  • 8. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward a consensus on the QALY.
    Drummond M; Brixner D; Gold M; Kind P; McGuire A; Nord E;
    Value Health; 2009 Mar; 12 Suppl 1():S31-5. PubMed ID: 19250129
    [No Abstract]   [Full Text] [Related]  

  • 10. The ethics of age discrimination and cost-benefit accounting.
    Maundrell R; Kotalik J
    Issues Med Ethics; 1999; 7(4):118-20. PubMed ID: 16323328
    [No Abstract]   [Full Text] [Related]  

  • 11. The value of life: individual preferences and social choice. A comment to Magnus Johannesson.
    Nord E; Menzel P; Richardson J
    Health Econ; 2003 Oct; 12(10):873-7. PubMed ID: 14508871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of screening for HIV.
    da Silveira E
    N Engl J Med; 2005 May; 352(20):2137-9; author reply 2137-9. PubMed ID: 15906436
    [No Abstract]   [Full Text] [Related]  

  • 13. How should age at diagnosis impact treatment strategy in asymptomatic primary hyperparathyroidism? A cost-effectiveness analysis.
    Zanocco K; Sturgeon C
    Surgery; 2008 Aug; 144(2):290-8. PubMed ID: 18656638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The cost per year of life gained: trends and internal contradictions].
    van Dam J
    Ned Tijdschr Geneeskd; 2007 Feb; 151(7):441; author reply 441-2. PubMed ID: 17343145
    [No Abstract]   [Full Text] [Related]  

  • 15. At last, NICE to take over the Cancer Drugs Fund.
    Timmins N
    BMJ; 2016 Mar; 352():i1324. PubMed ID: 26951838
    [No Abstract]   [Full Text] [Related]  

  • 16. Reallocating resources: how should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the National Health Service?
    Pearson S; Littlejohns P
    J Health Serv Res Policy; 2007 Jul; 12(3):160-5. PubMed ID: 17716419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness in goal-directed therapy: are the dollars spent worth the value?
    Ebm CC; Sutton L; Rhodes A; Cecconi M
    J Cardiothorac Vasc Anesth; 2014 Dec; 28(6):1660-6. PubMed ID: 25479922
    [No Abstract]   [Full Text] [Related]  

  • 18. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
    Schlander M
    J Med Ethics; 2008 Jul; 34(7):534-9. PubMed ID: 18591289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prioritizing health technologies in a Primary Care Trust.
    Wilson E; Sussex J; Macleod C; Fordham R
    J Health Serv Res Policy; 2007 Apr; 12(2):80-5. PubMed ID: 17407656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.